Placenta-on-Chip Recreates 4 Key Functions, Could Slash Animal Drug Tests

For obstetricians, pharmacologists, and regulatory safety officers, a lingering blind spot has always been the placental barrier—the dynamic interface determining fetal drug exposure during pregnancy. This new platform finally delivers a scalable, human-relevant tool to test drug transfer and toxicity in a controlled environment, without resorting to animal surrogates that often fail to predict human outcomes.

A team from the ICMR-National Institute for Research on Women’s Health (ICMR-NIRRCH), Mumbai, in collaboration with IIT Bombay, has developed an indigenous ‘placenta-on-chip’ platform that successfully recreates the core barrier functions of the human placenta. Published in the journal Biofabrication, the microphysiological system addresses a longstanding challenge in reproductive medicine: the inability to study the placenta directly during pregnancy due to ethical and technical constraints. The placenta acts as the fetus’s life-support, handling nutrient delivery, waste removal, hormone secretion, and immune protection, yet it remains one of the least understood human organs. This Indian innovation now provides a controllable, laboratory-based window into its workings.

“

The market for organ-on-chip technology is projected to grow from about $170 million in 2025 to over $630 million by 2032 (per market research), driven by demand for predictive human models in drug discovery.

The device is a bioengineered chip that grows a layer of human placental cells to mimic the maternal-fetal interface. According to the researchers, it successfully reproduces hormone production, transports glucose from the maternal to the fetal side, clears metabolic waste products like urea, and maintains a selective barrier—essential functions sustaining pregnancy. Notably, the platform also responds to hyperglycaemic conditions, making it a direct model for gestational diabetes, a condition affecting roughly 14% of pregnancies globally according to IDF data. This quadruple functional reproduction elevates the chip beyond simpler models that only demonstrate structural placental features.

What sets this platform apart from existing placenta-on-chip systems globally is its design philosophy. Most advanced organ-on-chip systems require intricate microfluidic pumps, continuous perfusion, and expensive infrastructure, limiting their use to a handful of highly specialized labs. The Indian team specifically engineered this chip to be simple, scalable, and compatible with conventional laboratory workflows—standard cell culture incubators and microscopes. This design choice dramatically lowers the barrier to entry for research laboratories worldwide, potentially democratizing placental research. The chip’s compatibility with off-the-shelf lab equipment also means it can be mass-produced more affordably, a crucial factor for resource-limited settings across Asia, Africa, and Latin America where maternal mortality and pregnancy complications remain high.

From a healthcare and pharmaceutical perspective, the implications are substantial. The placenta is a critical gatekeeper for fetal exposure to drugs, environmental toxins, and pathogens. Currently, understanding a drug’s maternal-fetal transfer relies heavily on animal models—often rodents or guinea pigs with placentas structurally dissimilar to humans—or indirect ex vivo perfusion of donated term placentas that are only viable for a few hours. This chip offers a standardized, human-relevant platform to test drug permeability, toxicity, and even infection mechanisms consistently. It could accelerate regulatory toxicology assessments while reducing animal testing, aligning with the FDA’s push for alternative methods under the Modernization Act 2.0 and EMA’s similar efforts.

The market for organ-on-chip technology is projected to grow from about $170 million in 2025 to over $630 million by 2032 (per market research), driven by demand for predictive human models in drug discovery. The Indian placenta-on-chip fits into this trajectory as a specialized segment targeting the $48 billion global maternal health market. It could attract licensing interest from biotech firms developing prenatal therapeutics or from CROs looking to offer placental transfer assays as a service. The fact that it is an indigenous development also positions India’s bioengineering ecosystem as a competitive player in the organ-on-chip space, which has been dominated by US- and Europe-based entities like Emulate, Mimetas, and TissUse.